Skip to main content
. 2020 May 31;12(6):1427. doi: 10.3390/cancers12061427

Figure 3.

Figure 3

RL2 induces marginal caspase-3 activity and BID processing. (A,B) MDA-MB-231 cells were pre-treated for one hour with 50 µM pan-caspase inhibitor zVAD-fmk and stimulated with 200 µg/mL RL2 as indicated. (A) Caspase-3/-7-activity was determined by Caspase-Glo3/7® Assay. Means and standard deviations of caspase activity are shown in relative units (RU) for three independent experiments and statistically analyzed by paired student t-test. (B) ATP levels were measured using the Cell Titer-Glo®-Luminescent Cell Viability Assay. Mean and standard deviation are shown for three independent experiments. The statistical analysis was carried out by paired student t-test. (C) MDA-MB-231 cells were stimulated with 200 µg/mL RL2 or 75 ng/mL TRAIL (positive control) for indicated periods of time, and subjected to Western Blot analysis with the indicated antibodies. One representative Western Blot out of three independent experiments along with its quantification is shown in Figure S2. ns (not significant; p > 0.05), * (significant; p < 0.05).